After Oppenheimer and Piper Jaffray gave Tivity Health Inc (NASDAQ: TVTY) a Buy rating last month, the company received another Buy, this time from Barrington. Analyst Michael Petusky maintained a Buy rating on Tivity Health Inc today and set a price target of $40. The company’s shares closed yesterday at $21.65, close to its 52-week low of $20.64.
Petusky wrote:
“We had been previously modeling $645.2 million in revenue, $149.0 million in EBITDA and $106.8 million in FCF.”
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 7.5% and a 51.2% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Merit Medical Systems, and Lemaitre Vascular.
Tivity Health Inc has an analyst consensus of Strong Buy, with a price target consensus of $36.20, implying a 67.2% upside from current levels. In a report released today, Oppenheimer also reiterated a Buy rating on the stock with a $31 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $44.35 and a one-year low of $20.64. Currently, Tivity Health Inc has an average volume of 1.22M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tivity Health, Inc. engages in the development and provision of network solutions and health management services. It offers rehabilitative therapy, chiropractic procedure, alternative medicines, and health and fitness programs under the SilverSneakers, Prime Fitness, and WholeHealth Living trademarks.
